Subotheni Thavaneswaran

St Vincent's Hospital
Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Journal: Future oncology (London, England)

Published: June 16, 2026

Risk Factors in Sporadic Early-Onset Colorectal Cancer, Current Evidence and Emerging Insights: A Systematic Review.

Risk Factors in Sporadic Early-Onset Colorectal Cancer, Current Evidence and Emerging Insights: A Systematic Review.

Journal: Cancers

Published: April 13, 2026

Genomic Therapy Matching in Rare and Refractory Cancers.

Genomic Therapy Matching in Rare and Refractory Cancers.

Journal: JAMA oncology

Published: March 05, 2026

Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation.

Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation.

Journal: JCO precision oncology

Published: February 13, 2026

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions.

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions.

Journal: JCO precision oncology

Published: December 22, 2025

Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma.

Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma.

Journal: JTO clinical and research reports

Published: December 09, 2025

Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas-a cohort study and patterns of care survey.

Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas-a cohort study and patterns of care survey.

Journal: Neuro-oncology practice

Published: October 13, 2025

A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.

A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 04, 2025

Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language Models.

Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language Models.

Journal: Studies in health technology and informatics

Published: August 08, 2025

Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand.

Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand.

Journal: Current oncology (Toronto, Ont.)

Published: February 17, 2025

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.

Journal: Cancer medicine

Published: February 14, 2025

Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma.

Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma.

Journal: BMJ open

Published: February 10, 2025

Showing 1-12 of 33

Last Updated: 09/26/2026